Vascular News 82 – June 2019

479

In this issue:

  • CX audience deems paclitaxel not dangerous, while vascular pathologist says establishing the truth takes time (p.1)
  • EVAR funding threatened, while a strategy for safe, cost-effective repair is “just around the corner” (p.1)
  • Marianne Broadmann outlines follow-up and surveillance protocols after endovascular treatments for peripheral arterial disease (p.22)
  • Profile: Kim Hodgson (p.26)

(Visited 69 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here